Combined Analysis of Protein Induced by Prothrombin Induced by Vitamin K Absence (PIVKA) and Alpha-L-Fucosidase (AFU) with Alpha-Fetoprotein (AFP) May Improve the Diagnostic Efficacy for Liver Cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis B.
{"title":"Combined Analysis of Protein Induced by Prothrombin Induced by Vitamin K Absence (PIVKA) and Alpha-L-Fucosidase (AFU) with Alpha-Fetoprotein (AFP) May Improve the Diagnostic Efficacy for Liver Cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis B.","authors":"Haisong Hou, Ruiqiang Weng, Liu Liang, Wendao Han","doi":"10.2147/IJGM.S547252","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The aim of this study was to explore the value of biomarkers such as prothrombin induced by vitamin K absence (PIVKA), osteopontin (OPN), α-L-fucoidase (AFU), interleukin-6 (IL-6), and Golgi protein 73 (GP73) in the diagnosis of chronic hepatitis B (CHB), hepatitis B liver cirrhosis (HBV-LC), and hepatocellular carcinoma (HCC).</p><p><strong>Methods: </strong>A total of 264 male patients were included in this study, including CHB (n=88), HBV-LC (n=88), and HCC (n=88). The levels of PIVKA, OPN, AFU, alpha-fetoprotein (AFP), IL6, and GP73 of the subjects were detected respectively, and the differences in the levels of serum PIVKA, OPN, AFU, AFP, IL6 and GP73 among the groups were compared. The correlations among various indicators were analyzed, and the diagnostic value of these indicators for HBV-LC and HCC was evaluated through the receiver operating characteristic (ROC) curve analysis.</p><p><strong>Results: </strong>The levels of PIVKA, OPN, AFP, AFU, IL6, and GP73 in patients with HBV-LC, HCC were significantly higher than those in patients with CHB, respectively. In patients with HBV-LC and HCC, no significant correlation was shown between AFP and other markers, suggesting that AFP may have an independent mechanism of action different from other markers in HBV-LC and HCC. OPN had the highest diagnostic efficacy, with an area under the ROC curve (AUC) of 0.855 in diagnosis of HBV-LC, followed by GP73 and IL6. AFU had the highest diagnostic efficacy in diagnosis of HCC, followed by AFP and OPN. In terms of combined detection, the diagnostic efficacy of AFP+AFU (AUC=0.785, 95% CI: 0.714-0.855) and AFP+PIVKA (AUC=0.635, 95% CI: 0.553-0.718) were better than AFP in diagnosing HBV-LC; and the diagnostic efficacy of AFP+AFU (AUC=0.878, 95% CI: 0.822-0.934) was better than AFP in diagnosing HCC.</p><p><strong>Conclusion: </strong>Combined analysis of PIVKA and AFU with AFP may improve the diagnostic efficacy for HBV-LC and HCC in CHB.</p>","PeriodicalId":14131,"journal":{"name":"International Journal of General Medicine","volume":"18 ","pages":"6031-6042"},"PeriodicalIF":2.0000,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12499579/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of General Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/IJGM.S547252","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The aim of this study was to explore the value of biomarkers such as prothrombin induced by vitamin K absence (PIVKA), osteopontin (OPN), α-L-fucoidase (AFU), interleukin-6 (IL-6), and Golgi protein 73 (GP73) in the diagnosis of chronic hepatitis B (CHB), hepatitis B liver cirrhosis (HBV-LC), and hepatocellular carcinoma (HCC).
Methods: A total of 264 male patients were included in this study, including CHB (n=88), HBV-LC (n=88), and HCC (n=88). The levels of PIVKA, OPN, AFU, alpha-fetoprotein (AFP), IL6, and GP73 of the subjects were detected respectively, and the differences in the levels of serum PIVKA, OPN, AFU, AFP, IL6 and GP73 among the groups were compared. The correlations among various indicators were analyzed, and the diagnostic value of these indicators for HBV-LC and HCC was evaluated through the receiver operating characteristic (ROC) curve analysis.
Results: The levels of PIVKA, OPN, AFP, AFU, IL6, and GP73 in patients with HBV-LC, HCC were significantly higher than those in patients with CHB, respectively. In patients with HBV-LC and HCC, no significant correlation was shown between AFP and other markers, suggesting that AFP may have an independent mechanism of action different from other markers in HBV-LC and HCC. OPN had the highest diagnostic efficacy, with an area under the ROC curve (AUC) of 0.855 in diagnosis of HBV-LC, followed by GP73 and IL6. AFU had the highest diagnostic efficacy in diagnosis of HCC, followed by AFP and OPN. In terms of combined detection, the diagnostic efficacy of AFP+AFU (AUC=0.785, 95% CI: 0.714-0.855) and AFP+PIVKA (AUC=0.635, 95% CI: 0.553-0.718) were better than AFP in diagnosing HBV-LC; and the diagnostic efficacy of AFP+AFU (AUC=0.878, 95% CI: 0.822-0.934) was better than AFP in diagnosing HCC.
Conclusion: Combined analysis of PIVKA and AFU with AFP may improve the diagnostic efficacy for HBV-LC and HCC in CHB.
期刊介绍:
The International Journal of General Medicine is an international, peer-reviewed, open access journal that focuses on general and internal medicine, pathogenesis, epidemiology, diagnosis, monitoring and treatment protocols. The journal is characterized by the rapid reporting of reviews, original research and clinical studies across all disease areas.
A key focus of the journal is the elucidation of disease processes and management protocols resulting in improved outcomes for the patient. Patient perspectives such as satisfaction, quality of life, health literacy and communication and their role in developing new healthcare programs and optimizing clinical outcomes are major areas of interest for the journal.
As of 1st April 2019, the International Journal of General Medicine will no longer consider meta-analyses for publication.